GlassScriptPhysician profile
Xuxia Wu
NPI 1124362348
$3,669.38
in general payments reported to CMS, 2019-2025
19 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $12.17 · 2021: $151 · 2022: $462 · 2023: $888 · 2024: $834 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,918.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $763.37 | 2023-2025 | Airsupra, Farxiga |
| Gilead Sciences, INC. | $560.26 | 2023-2025 | |
| Amgen INC. | $410.56 | 2023-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $282.75 | 2022-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $205.97 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $185.59 | 2022 | |
| Novo Nordisk INC | $178.02 | 2022-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $167.80 | 2021-2025 | Viberzi, Linzess |
| Merck Sharp & Dohme LLC | $149.68 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
| Allergan, INC. | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.90 | 2025 | Dupixent |
| Amarin Pharma, INC. | $117.44 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.73 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $94.92 | 2023-2025 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $54.36 | 2024 | Unithroid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $48.41 | 2021-2022 | |
| Pfizer INC. | $32.02 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $29.25 | 2024 | Voquezna |
| Ardelyx, INC. | $25.35 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xuxia Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.